Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis

Blood (2023) 142 (Supplement 1): 1322.

https://doi.org/10.1182/blood-2023-186721

Published: 2023

Journal Articles

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Blood (2022) 140 (Supplement 1): 6279–6281.

https://doi.org/10.1182/blood-2022-169696

Published: 2022

Journal Articles

Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 537–538.

https://doi.org/10.1182/blood-2022-165464

Published: 2022

Journal Articles

Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials

Cyril Quivoron, Helene Lecourt, Jean-Marie Michot, Julien Lazarovici, Julien Rossignol, David Ghez, Veronique Vergé, Veronique Saada, Alina Danu, Vincent Ribrag

Blood (2021) 138 (Supplement 1): 3763.

https://doi.org/10.1182/blood-2021-149369

Published: 2021

Journal Articles

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

Blood (2021) 137 (24): 3390–3402.

https://doi.org/10.1182/blood.2020008729

Published: 2021

Includes: Supplemental data

Journal Articles

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139971

Published: 2020

Journal Articles

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sabine Khalife-Hachem, Khalil Saleh, MD, Florence Pasquier, MD PhD, Anthony Tarabay, Cyril Quivoron, Sophie Cotteret, Christophe Willekens, MD, Veronique Saada, Ines-Maria Vaz-Luis, Suzette Delaloge, Alexandra Leary, Hana Raslova, PhD, Filippo Rosselli, Olivier Caron, Iléana Antony-Debre, PhD, Eric Solary, MD PhD, Stephane de Botton, MD PhD, Christophe Marzac, MD, Jean-Baptiste Micol, MD

Blood (2019) 134 (Supplement_1): 3722.

https://doi.org/10.1182/blood-2019-126872

Published: 2019

Journal Articles

Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum

Blood (2019) 133 (25): 2718–2724.

https://doi.org/10.1182/blood-2019-01-895698

Published: 2019

Includes: Supplemental data

Journal Articles

ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

Blood (2018) 132 (Supplement 1): 1482.

https://doi.org/10.1182/blood-2018-99-110366

Published: 2018

Journal Articles

Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond–like syndrome

Blood (2018) 132 (12): 1318–1331.

https://doi.org/10.1182/blood-2017-12-820308

Published: 2018

Includes: Supplemental data

Journal Articles

Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

Christophe Willekens, MD, Veronique Saada, Sophie Broutin, Julia Delahousse, Aline Renneville, MDPhD, Cynthia Petrovanu, Christophe Marzac, Jean-Baptiste Micol, MD PhD, Éric Solary, MD PhD, Florence Pasquier, MD PhD, Julien Lazarovici, MD, Vincent Ribrag, Claude Preudhomme, PharmD, PhD, Cyril Quivoron, Virginie Penard-Lacronique, PhD, Angelo Paci, Stephane de Botton, MD PhD

Blood (2017) 130 (Supplement 1): 1313.

https://doi.org/10.1182/blood.V130.Suppl_1.1313.1313

Published: 2017

Journal Articles

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 724.

https://doi.org/10.1182/blood.V130.Suppl_1.724.724

Published: 2017

Journal Articles

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

Alina Danu, MD, Sophie Cotteret, PhD, Ludovic Lacroix, Véronique Saada, PharmD, Véronique Vergé, MD, Nathalie Auger, Julien Lazarovici, MD, Edith Carton, Jonathan Farhi, Khalil Saleh, MD, David Ghez, PhD MD, Claude Chahine, MD, Jean-Marie Michot, MD, Vincent Ribrag, MD

Blood (2016) 128 (22): 5638.

https://doi.org/10.1182/blood.V128.22.5638.5638

Published: 2016

Journal Articles

Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

Khalil Saleh, MD, Christophe Willekens, MD, Jean Edouard Martin, Myriam Kossai, Nadine Khalifé-Saleh, MD, Véronique Saada, PharmD, Nathalie Auger, Alina Danu, MD, Julien Lazarovici, MD, Alexandra Leary, Suzette Delaloge, Jean Henri Bourhis, MD PhD, Éric Solary, MD PhD, Serge Koscielny, Stephane de Botton, Jean-Baptiste Micol, MD PhD

Blood (2016) 128 (22): 4006.

https://doi.org/10.1182/blood.V128.22.4006.4006

Published: 2016

Journal Articles

Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

Stanley Chun-Wei Lee, PhD, Khrystyna Dilai, Esther A. Obeng, MDPhD, Eunhee Kim, PhD, Jean-Baptiste Micol, MD PhD, Akihide Yoshimi, MD PhD, Christophe Willekens, MD, Daichi Inoue, Véronique Saada, PharmD, Hana Cho, Young Rock Chung, MS, James Palacino, PhD, Michael Seiler, PhD, Silvia Buonamici, PhD, Peter Smith, Benjamin L. Ebert, MD PhD, Robert Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2016) 128 (22): 961.

https://doi.org/10.1182/blood.V128.22.961.961

Published: 2016

Journal Articles

A Series of 116 Therapy-Related Myeloid Neoplasms (t-MN) Patients from 2 French Comprehensive Cancer Centers

Hind Bennani, PharmD, Véronique Saada, PharmD, Christophe Willekens, MD, Jacques Vargaftig, MD

Blood (2015) 126 (23): 1322.

https://doi.org/10.1182/blood.V126.23.1322.1322

Published: 2015

Journal Articles

Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation

Christophe Willekens, MD, Angelo Paci, Serge Koscielny, Alice Marceau, Jean-Baptiste Micol, MD, Sophie Broutin, Cyril Quivoron, Véronique Saada, Vianney Poinsignon, Franck Griscelli, Vincent Ribrag, MD, Cristina Castilla-Llorente, Claude Preudhomme, Virginie Lacronique-Penard, Stéphane De Botton

Blood (2015) 126 (23): 3833.

https://doi.org/10.1182/blood.V126.23.3833.3833

Published: 2015

Journal Articles

Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

Christophe Willekens, MD, Jean-Baptiste Micol, MD, Vianney Poinsignon, Cyril Quivoron, Véronique Saada, Sophie Broutin, Marie Terroir-Cassou-Mounat, David Ghez, Jean-Henri Bourhis, MD PhD, Jacques Bosq, MD, Vincent Ribrag, MD, Angelo Paci, Virginie Lacronique-Penard, Stéphane De Botton

Blood (2015) 126 (23): 3835.

https://doi.org/10.1182/blood.V126.23.3835.3835

Published: 2015

Journal Articles

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Blood (2015) 125 (23): 3618–3626.

https://doi.org/10.1182/blood-2015-01-620781

Published: 2015

Includes: Supplemental data

Journal Articles

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

Erica Hansen, Cyril Quivoron, Kim Straley, René M Lemieux, Janeta Popovici-Muller, Hossein Sadrzadeh, Amir T Fathi, Camelia Gliser, Muriel David, Véronique Saada, Jean-Baptiste Micol, Olivier Bernard, Marion Dorsch, Hua Yang, Michael Su, Sam Agresta, Stéphane de Botton, Virginie Penard-Lacronique, Katharine Yen

Blood (2014) 124 (21): 3734.

https://doi.org/10.1182/blood.V124.21.3734.3734

Published: 2014

NARROW

1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum

ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond–like syndrome

Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

A Series of 116 Therapy-Related Myeloid Neoplasms (t-MN) Patients from 2 French Comprehensive Cancer Centers

Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation

Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only